Cargando…
Genetically Engineered Mouse Models for Liver Cancer
Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xen...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016809/ https://www.ncbi.nlm.nih.gov/pubmed/31861541 http://dx.doi.org/10.3390/cancers12010014 |
_version_ | 1783497060728700928 |
---|---|
author | Cho, Kyungjoo Ro, Simon Weonsang Seo, Sang Hyun Jeon, Youjin Moon, Hyuk Kim, Do Young Kim, Seung Up |
author_facet | Cho, Kyungjoo Ro, Simon Weonsang Seo, Sang Hyun Jeon, Youjin Moon, Hyuk Kim, Do Young Kim, Seung Up |
author_sort | Cho, Kyungjoo |
collection | PubMed |
description | Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xenograft models, and genetically engineered mouse (GEM) models, are valuable tools to reproduce human HCC biopathology and biochemistry. These models can be used to identify potential biomarkers, evaluate potential novel therapeutic drugs in pre-clinical trials, and develop molecular target therapies. Considering molecular target therapies, a novel approach has been developed to create genetically engineered murine models for HCC, employing hydrodynamics-based transfection (HT). The HT method, coupled with the Sleeping Beauty transposon system or the CRISPR/Cas9 genome editing tool, has been used to rapidly and cost-effectively produce a variety of HCC models containing diverse oncogenes or inactivated tumor suppressor genes. The versatility of these models is expected to broaden our knowledge of the genetic mechanisms underlying human hepatocarcinogenesis, allowing the study of premalignant and malignant liver lesions and the evaluation of new therapeutic strategies. Here, we review recent advances in GEM models of HCC with an emphasis on new technologies. |
format | Online Article Text |
id | pubmed-7016809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70168092020-02-28 Genetically Engineered Mouse Models for Liver Cancer Cho, Kyungjoo Ro, Simon Weonsang Seo, Sang Hyun Jeon, Youjin Moon, Hyuk Kim, Do Young Kim, Seung Up Cancers (Basel) Review Liver cancer is the fourth leading cause of cancer-related death globally, accounting for approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as chemically-induced models, xenograft models, and genetically engineered mouse (GEM) models, are valuable tools to reproduce human HCC biopathology and biochemistry. These models can be used to identify potential biomarkers, evaluate potential novel therapeutic drugs in pre-clinical trials, and develop molecular target therapies. Considering molecular target therapies, a novel approach has been developed to create genetically engineered murine models for HCC, employing hydrodynamics-based transfection (HT). The HT method, coupled with the Sleeping Beauty transposon system or the CRISPR/Cas9 genome editing tool, has been used to rapidly and cost-effectively produce a variety of HCC models containing diverse oncogenes or inactivated tumor suppressor genes. The versatility of these models is expected to broaden our knowledge of the genetic mechanisms underlying human hepatocarcinogenesis, allowing the study of premalignant and malignant liver lesions and the evaluation of new therapeutic strategies. Here, we review recent advances in GEM models of HCC with an emphasis on new technologies. MDPI 2019-12-19 /pmc/articles/PMC7016809/ /pubmed/31861541 http://dx.doi.org/10.3390/cancers12010014 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cho, Kyungjoo Ro, Simon Weonsang Seo, Sang Hyun Jeon, Youjin Moon, Hyuk Kim, Do Young Kim, Seung Up Genetically Engineered Mouse Models for Liver Cancer |
title | Genetically Engineered Mouse Models for Liver Cancer |
title_full | Genetically Engineered Mouse Models for Liver Cancer |
title_fullStr | Genetically Engineered Mouse Models for Liver Cancer |
title_full_unstemmed | Genetically Engineered Mouse Models for Liver Cancer |
title_short | Genetically Engineered Mouse Models for Liver Cancer |
title_sort | genetically engineered mouse models for liver cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016809/ https://www.ncbi.nlm.nih.gov/pubmed/31861541 http://dx.doi.org/10.3390/cancers12010014 |
work_keys_str_mv | AT chokyungjoo geneticallyengineeredmousemodelsforlivercancer AT rosimonweonsang geneticallyengineeredmousemodelsforlivercancer AT seosanghyun geneticallyengineeredmousemodelsforlivercancer AT jeonyoujin geneticallyengineeredmousemodelsforlivercancer AT moonhyuk geneticallyengineeredmousemodelsforlivercancer AT kimdoyoung geneticallyengineeredmousemodelsforlivercancer AT kimseungup geneticallyengineeredmousemodelsforlivercancer |